IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY

被引：2
|
作者：
Emery, P. [1 ]
Bingham, C. O. [2 ]
Burmester, G. -R. [3 ]
Bykerk, V. P. [4 ]
Furst, D. E. [5 ]
Mariette, X. [6 ]
Purcaru, O. [7 ]
Coteur, G. [7 ]
VanLunen, B. [8 ]
Weinblatt, M. [9 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Paris Sud, Hop Univ Paris Sud, AP HP, Paris, France
[7] UCB Pharma, Brussels, Belgium
[8] UCB Pharma, Raleigh, NC USA
[9] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.1499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0165
引用
收藏
页码：712 / 713
页数：2
相关论文
共 50 条
  • [31] Patient-reported outcomes following 24 weeks of treatment with upadacitinib in adults with non-segmental vitiligo: results from a phase 2, randomized, double-blind, dose-ranging study
    Ezzedine, Khaled
    Soliman, Ahmed M.
    Rosmarin, David
    Pandya, Amit G.
    Schlosser, Bethanee J.
    van Geel, Nanja
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II63 - II64
  • [32] RANDOMIZATION TO PATIENT-REPORTED RAPID3 VERSUS PHYSICIAN-BASED CDAI TOOLS FOR PREDICTION OF TREATMENT RESPONSE AND ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB PEGOL: RESULTS FROM THE PREDICT STUDY
    Curtis, J. R.
    Churchill, M.
    Kivitz, A.
    Samad, A.
    Gauer, L.
    Coteur, G.
    Gervitz, L.
    Koetse, W.
    Melin, J.
    Yazici, Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 382 - 382
  • [33] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
  • [34] IMPROVEMENT IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH ADALIMUMAB PLUS METHOTREXATE: WORK OUTCOMES AND THEIR CORRELATIONS WITH CLINICAL AND RADIOGRAPHIC MEASURES FROM A RANDOMIZED CONTROLLED TRIAL COMPANION STUDY
    van Vollenhoven, R.
    Cifaldi, M.
    Ray, S.
    Chen, N.
    Weisman, M. H.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A485 - A485
  • [35] A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
    Kavanaugh, Arthur
    Decktor, Dennis L.
    Fan, Chunpeng
    van Adelsberg, Janet
    Martincova, Renata
    Genovese, Mark C.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1233 - S1234
  • [36] Patient-Reported Outcomes of Azelaic Acid Foam 15% for Patients With Papulopustular Rosacea: Secondary Efficacy Results From a Randomized, Controlled, Double-blind, Phase 3 Trial
    Tyring, Stephen
    Solomon, James A.
    Staedtler, Gerald
    Lott, Jason P.
    Nkulikiyinka, Richard
    Shakery, Kaweh
    [J]. CUTIS, 2016, 98 (04): : 269 - 275
  • [37] Magnetic resonance imaging (MRI) assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomized, double-blind, placebo-controlled Phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8, and 16
    Ostergaard, M.
    Jacobsson, L.
    Schaufelberger, C.
    Sejer-Hansen, M.
    Bijlsma, J.
    Dudek, A.
    Rell-Bakalarska, M.
    Staelens, F.
    Haake, R.
    Sundman-Engberg, B.
    Bliddal, H.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 14 - 14
  • [38] Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
    van der Heijde, Desiree
    Braun, Jurgen
    Rudwaleit, Martin
    Purcaru, Oana
    Kavanaugh, Arthur
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S592 - S592
  • [39] Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study.
    Sieper, Joachim
    Kivitz, Alan J.
    Van Tubergen, A. M.
    Deodhar, Atul A.
    Coteur, Geoffroy
    Woltering, Franz
    Landewe, Robert B. M.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S243 - S243
  • [40] MAGNETIC RESONANCE IMAGING-ASSESSMENT OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIIB STUDY APPLYING MAGNETIC RESONANCE IMAGING AT WEEKS 0, 1, 2, 4, 8 AND 16
    Ostergaard, M.
    Jacobsson, L.
    Schaufelberger, C.
    Sejer-Hansen, M.
    Bijlsma, J.
    Dudek, A.
    Rell-Bakalarska, M.
    Staelens, F.
    Haake, R.
    Sundman-Engberg, B.
    Bliddal, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 472 - 472
12345